Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01639560 · ClinicalTrials.gov registry record · Phase 4

Varenicline for Light Smokers

A Phase 4 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
93
Enrollment target

NCT01639560: Completed Phase 4 study, sponsored by Mayo Clinic.

NCT01639560 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 93 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01639560, a Phase 4 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
93 participants
Enrollment target

Study Summary

The purpose of this study is to determine if varenicline is effective in treating tobacco dependence in adults who smoke 5-10 cigarettes per day.

Primary Outcome

To determine the efficacy of 12 weeks of varenicline therapy in achieving increased smoking abstinence rates in light smokers. Point prevalence is defined as no smoking in the past 7 days.

Interventions

  • DRUG Placebo
  • DRUG Varenicline

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2013-01
Est. Completion 2016-06
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT01639560 record still lists

NCT01639560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01639560 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01639560 about?

NCT01639560 is a clinical study titled "Varenicline for Light Smokers". The purpose of this study is to determine if varenicline is effective in treating tobacco dependence in adults who smoke 5-10 cigarettes per day.

What is the current status of trial NCT01639560?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2013-01. Estimated completion is 2016-06.

What interventions are being tested in trial NCT01639560?

The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).

Who is sponsoring clinical trial NCT01639560?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01639560's enrollment target sits among peer trials

93 874th of 2000 higher than 1,125 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01639560, the US trial registry maintained by the National Library of Medicine. NCT01639560 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.